{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:15:47Z","timestamp":1788239747244,"version":"build-2803163510"},"reference-count":12,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.59556\/japi.74.1627","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:23:36Z","timestamp":1788236616000},"page":"74-76","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Challenges and Predictors of Success in Glucagon-like Peptide-1 Receptor Agonist Therapy"],"prefix":"10.59556","volume":"74","author":[{"given":"Nitin Mohaniraj","family":"Patankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma Jain","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20260901042334_B1","doi-asserted-by":"crossref","first-page":"1834\u2013","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375:","author":"Marso","year":"2016;","journal-title":"N Engl J Med"},{"key":"key20260901042334_B2","doi-asserted-by":"crossref","first-page":"605\u2013","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.","volume":"6:","author":"Tuttle","year":"2018;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(4):","key":"key20260901042334_B3","doi-asserted-by":"crossref","first-page":"3386\u2013","DOI":"10.1111\/dom.70535","article-title":"Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: a UK population-based cohort study by obesity and cardiovascular disease status.","volume":"28","author":"Ulrich","year":"2026;","journal-title":"Diabetes Obes Metab"},{"key":"key20260901042334_B4","doi-asserted-by":"crossref","first-page":"1613610.","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis.","volume":"16:","author":"Xie","year":"2025;","journal-title":"Front Pharmacol"},{"key":"key20260901042334_B5","doi-asserted-by":"crossref","first-page":"1226778.","DOI":"10.3389\/fphar.2023.1226778","article-title":"Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.","volume":"14:","author":"Feng","year":"2023;","journal-title":"Front Pharmacol"},{"issue":"(2):","key":"key20260901042334_B6","doi-asserted-by":"crossref","first-page":"175\u2013","DOI":"10.2337\/ds20-0025","article-title":"Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: a qualitative study.","volume":"34","author":"Polonsky","year":"2021;","journal-title":"Diabetes Spectr"},{"key":"key20260901042334_B7","doi-asserted-by":"crossref","first-page":"101102.","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2014 state-of-the-art.","volume":"46:","author":"Nauck","year":"2021;","journal-title":"Mol Metab"},{"key":"key20260901042334_B8","doi-asserted-by":"crossref","first-page":"2701\u2013","DOI":"10.2147\/DMSO.S308322","article-title":"Psychosocial determinants of treatment adherence in patients with type 2 diabetes \u2014 a review.","volume":"14:","author":"\u015awi\u0105toniowska-Lonc","year":"2021;","journal-title":"Diabetes Metab Syndr Obes"},{"key":"key20260901042334_B9","unstructured":"World Economic Forum. How biowearables are transforming diabetes and patient care [Internet]. 2025 Jan [cited 2026 Jul 14]. Available from: www.weforum.org\/stories\/2025\/01\/how-biowearables-are-transforming-diabetes-care-and-empowering-patients\/"},{"key":"key20260901042334_B10","doi-asserted-by":"crossref","first-page":"503\u2013","DOI":"10.1056\/NEJMoa2107519","article-title":"SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385:","author":"Fr\u00edas","year":"2021;","journal-title":"N Engl J Med"},{"key":"key20260901042334_B11","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01211-4","article-title":"Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.","volume":"20:","author":"Yang","year":"2021;","journal-title":"Cardiovasc Diabetol"},{"issue":"(3):","key":"key20260901042334_B12","first-page":"276\u2013","article-title":"Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.","volume":"29","author":"Zhang","year":"2023;","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:23:38Z","timestamp":1788236618000},"score":1,"resource":{"primary":{"URL":"http:\/\/japi.org\/article\/japi-74-8-64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.59556\/japi.74.1627"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1627","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}